Last mentioned: Mar 18, 2026
Q4 Earnings Call
Management details strategic advances and future clinical roadmap.
Data Readout
Anticipated Phase 2b/3 data for Haduvio in chronic cough indications.
Fiscal Year End
Trevi concludes 2025 with key clinical milestones met for IPF chronic cough.
Q4 Strategic Pivot
Trevi refocuses resources on Haduvio's late-stage respiratory trials.
Trevi Therapeutics and Cibus Inc reported Q4 2025 results, highlighting a divergence in fiscal health as Trevi outperformed earnings expectations while Cibus faced mounting financial pressure. Both companies remain focused on high-stakes technical milestones, with Trevi advancing its lead asset Haduvio and Cibus pushing gene-edited crop traits toward commercialization.
Trevi Therapeutics reported significant strategic progress in its Q4 2025 earnings, focusing on the clinical development of Haduvio for chronic cough in IPF. While the company achieves key R&D milestones, the broader biotech sector continues to navigate a complex financial landscape characterized by high capital costs and strategic realignments.